“In 2015, when I started in this field…. people considered breast cancer a cold tumor,” Marleen Kok told the audience at the European Society of Medical Oncology’s 2022 Targeted Anticancer Therapy meeting (ESMO TAT). But the sensitivity of breast cancer to immunotherapy, or lack thereof, is “not a black and white phenomenon.”
Marker Therapeutics Inc.’s update from the safety lead-in stage of its phase II study of MT-401 in treating post-transplant acute myeloid leukemia saw response in one of the six participants. The results from the study of the multitumor-associated antigen-specific T-cell product also known as zelenoleucel saw firms such as Oppenheimer cut its target price for Marker to $5 from $8 and Piper Sandler to cut its target price from $5.50 to $4.
The overwhelming focus of research into the cellular immune response to SARS-CoV-2 has been investigating the reaction of vaccinated people, in an effort to establish correlates of protection required to fight off infection. But with a majority in many African and Asian countries still unvaccinated, it also is important to understand the natural cellular immune response, and to track the emergence of SARS-CoV-2 variants with the potential to escape immunity in these populations.
LONDON – T cells generated as a result of infection with common cold coronaviruses provide cross-protection against being infected with SARS-CoV-2, according to a new study.
LONDON – Intensive monitoring of health care workers at two hospitals in London showed that despite having a blood biomarker of infection, 58 of them did not test positive for COVID-19 at any point, suggesting they may have been clearing subclinical infections before seroconversion.
Marengo Therapeutics Inc. is opening up a new front in the war on cancer by selectively deploying a tumor-infiltrating subpopulation of T cells, which can be activated by a newly identified, antibody-based mechanism. The Cambridge, Mass.-based company is taking forward a scientific concept that has been germinating for several years at founding investor and company creator ATP, which has now launched the firm with an $80 million series A round. Marengo is gearing up for a first clinical trial in 2022. “It’s a new chapter in T-cell biology,” CEO Zhen Su told BioWorld.
There’s a whole group of biotechs trying to create a tougher next-generation CAR T-cell therapy that could have a powerful effect on solid tumors after the technology’s first successes in blood cancer. One of those is London-based Leucid Bio Ltd., which has just raised £11.5 million (nearly US$16 million) in series A financing to develop next-generation CAR T therapies that are able to make it through to solid tumors and attack them.
It's a good news, bad news scenario for exhausted T cells in chronic infections. Multiple groups of investigators reported in the July 26, 2021, online issue of NatureImmunology that even after a chronic hepatitis C virus infection was cured, T cells that had become dysfunctional during the infection retained epigenetic "scars" that prevented them from becoming fully functional memory T cells.
It's a good news, bad news scenario for exhausted T cells in chronic infections. Multiple groups of investigators reported in the July 26, 2021, online issue of NatureImmunology that even after a chronic hepatitis C virus infection was cured, T cells that had become dysfunctional during the infection retained epigenetic "scars" that prevented them from becoming fully functional memory T cells.
ISA Pharmaceuticals BV has closed a €26 million (US$30.76 million) funding round to advance its cancer immunotherapy product, ISA-101b, in the clinic, as the company aims to tackle the low response rates that hold back this therapeutic approach.